MIRA

MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

MIRA Pharmaceuticals, Inc. (MIRA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 9 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.6
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -16.9%
Price Return 12M -55.3%
Catalyst Signal 0.00
Market Cap $27.2M
TTM Revenue N/A
Price / Sales N/A
ROE -217.1%

Historical Factor Score Progression

Held C- for 9 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D+ (1.8) D (1.2) C- (2.1) C+ (2.6) C- (2.1)
2026-11-06 C+ (2.5) D+ (1.8) D (1.2) C- (1.9) C+ (2.7) C- (2.0)
2026-10-30 C+ (2.5) D+ (1.8) D (1.4) C- (1.9) C+ (2.7) C- (2.1)
2026-10-23 C+ (2.5) C- (1.9) D (1.3) D+ (1.8) C+ (2.6) C- (2.0)
2026-10-16 C+ (2.5) D+ (1.8) D (1.3) D+ (1.5) C+ (2.6) C- (2.0)
Page 1 of 3